NasdaqCM:CASI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has CASI Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CASI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: CASI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-2.4%

CASI

0.7%

US Biotechs

1.4%

US Market


1 Year Return

6.6%

CASI

40.9%

US Biotechs

22.6%

US Market

Return vs Industry: CASI underperformed the US Biotechs industry which returned 41.5% over the past year.

Return vs Market: CASI underperformed the US Market which returned 22.8% over the past year.


Shareholder returns

CASIIndustryMarket
7 Day-2.4%0.7%1.4%
30 Day5.9%5.2%4.9%
90 Day83.6%23.7%14.6%
1 Year6.6%6.6%43.2%40.9%25.4%22.6%
3 Year-16.0%-16.0%27.1%20.5%46.8%37.0%
5 Year187.6%187.6%58.4%46.0%132.0%106.1%

Long-Term Price Volatility Vs. Market

How volatile is CASI Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CASI Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

4.4x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CASI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CASI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CASI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CASI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CASI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CASI's PB Ratio (4.4x) is in line with the US Biotechs industry average.


Next Steps

Future Growth

How is CASI Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

35.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CASI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CASI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CASI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CASI's revenue (47.1% per year) is forecast to grow faster than the US market (10.5% per year).

High Growth Revenue: CASI's revenue (47.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CASI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CASI Pharmaceuticals performed over the past 5 years?

-43.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CASI is currently unprofitable.

Growing Profit Margin: CASI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CASI is unprofitable, and losses have increased over the past 5 years at a rate of 43% per year.

Accelerating Growth: Unable to compare CASI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CASI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: CASI has a negative Return on Equity (-40.58%), as it is currently unprofitable.


Next Steps

Financial Health

How is CASI Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CASI's short term assets ($83.3M) exceed its short term liabilities ($5.6M).

Long Term Liabilities: CASI's short term assets ($83.3M) exceed its long term liabilities ($15.9M).


Debt to Equity History and Analysis

Debt Level: CASI is debt free.

Reducing Debt: CASI currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CASI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CASI has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 39.1% each year.


Next Steps

Dividend

What is CASI Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CASI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CASI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CASI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CASI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CASI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Wei-Wu He (55 yo)

1.75yrs

Tenure

US$9,410,827

Compensation

Dr. Wei-Wu He, Ph.D. serves as Chairman and Chief Executive Officer at CASI Pharmaceuticals, Inc since April 2, 2019 and served as its Executive Chairman from February 23, 2018 until April 2, 2019. Dr. He ...


CEO Compensation Analysis

Compensation vs Market: Wei-Wu's total compensation ($USD9.41M) is above average for companies of similar size in the US market ($USD1.64M).

Compensation vs Earnings: Wei-Wu's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Wei-Wu He
Chairman & CEO1.75yrsUS$9.41m3.78%
$ 15.2m
Wei Zhang
President1.33yrsUS$956.10k0.016%
$ 65.5k
Alexander Zukiwski
Chief Medical Officer3.75yrsUS$961.35k0%
$ 0
Weihao Xu
CFO & Principal Accounting Officer0.083yrno data0.0081%
$ 32.5k
Cynthia Hu
COO, General Counsel & Secretary12.08yrsUS$467.10kno data
James Goldschmidt
Senior Vice President of Business Development1.75yrsno datano data

1.8yrs

Average Tenure

55yo

Average Age

Experienced Management: CASI's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Wei-Wu He
Chairman & CEO1.75yrsUS$9.41m3.78%
$ 15.2m
Quan Zhou
Independent Director4.58yrsUS$139.00k0%
$ 0
Ruijin Huang
Independent Director7.75yrsUS$144.85k0.00015%
$ 604.2
Rajesh Shrotriya
Independent Director6.33yrsUS$125.60k0%
$ 0
Sue Eckhardt
Member of Scientific Advisory Board14.5yrsno datano data
Y. Wu
Independent Director7.75yrsUS$140.45k0%
$ 0
Ghassan Abou-Alfa
Member of Clinical Advisory Board5.5yrsno datano data
Franklin Salisbury
Independent Director6.58yrsUS$140.45k0%
$ 0
Robert Mayer
Member of Clinical Advisory Board5.5yrsno datano data

6.6yrs

Average Tenure

62yo

Average Age

Experienced Board: CASI's board of directors are considered experienced (6.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CASI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.6%.


Top Shareholders

Company Information

CASI Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CASI Pharmaceuticals, Inc.
  • Ticker: CASI
  • Exchange: NasdaqCM
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$402.817m
  • Shares outstanding: 123.94m
  • Website: https://www.casipharmaceuticals.com

Number of Employees


Location

  • CASI Pharmaceuticals, Inc.
  • 9620 Medical Center Drive
  • Suite 300
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CASINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 1996
ENMNDB (Deutsche Boerse AG)YesCommon StockDEEURJun 1996

Biography

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/21 23:31
End of Day Share Price2021/01/21 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.